Hormone Research in Paediatrics
Original Paper
Baseline Inhibin B Levels for Diagnosis of Central Precocious Puberty in GirlsDe Filippo G.a, d · Rendina D.d · Nazzaro A.b · Lonardo F.c · Bouvattier C.e · Strazzullo P.daServizio di Endocrinologia Pediatrica, bUnità Operativa di Fisiopatologia della Riproduzione, cUnità Operativa di Genetica Medica, Azienda Ospedaliera ‘Gaetano Rummo', Benevento, and dDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy; eService d'Endocrinologie et Diabétologie Pédiatrique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
Keywords: Central precocious pubertyInhibin BGirls |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 10, 2013
Accepted: July 25, 2013
Published online: September 17, 2013
Issue release date: October 2013
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Abstract
Aim: To evaluate the use of baseline inhibin B (INHB) levels to differentiate the progressive form (PF) from the non-progressive form (NPF) of central precocious puberty (CPP). Methods: A total of 62 girls were enrolled, 31 with PF and 31 with NPF. Using receiver operating characteristic (ROC) curves, we analysed the diagnostic performance of INHB in addition to other diagnostic tools used to differentiate the 2 forms of CPP. Results: INHB levels were higher in PF versus NPF (29.1 vs. 13.1 pg/ml; p < 0.001). The ROC area under the curve (AUC) was greatest for luteinizing hormone [LH; 0.807, standard error (SE) 0.069], followed by INHB (0.800, SE 0.067), ovarian volume (OV; 0.782, SE 0.070) and uterine volume (0.723, SE 0.076). In ROCs relative to a combination of such parameters, the AUC was greater for LH + INHB (0.972, SE 0.010), followed by OV + LH (0.841, SE 0.084) and OV + INHB (0.836, SE 0.075). The combination of INHB and LH (with cut-offs of 20 pg/ml and 0.2 IU/l, respectively) results in 98% sensitivity and specificity. Conclusion: Our results suggest that the addition of basal INHB values to baseline LH levels provides a reliable method to identify PF. Further replication studies are needed to definitively prove or disprove the utility and advantages of INHB levels as part of the work-up of CPP.
© 2013 S. Karger AG, Basel
Related Articles:
References
- Carel JC, Léger J: Precocious puberty. N Engl J Med 2008;358:2366-2377.
- Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP: The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 2003;24:668-693.
- Lee PA: Central precocious puberty. An overview of diagnosis, treatment and outcome. Endocrinol Metab Clin North Am 1999;28:901-911.
- Iughetti L, Predieri B, Gallo C, Livio L, Milioli S, Forese S, Bernasconi S: Diagnosis of central precocious puberty: endocrine assessment. J Pediatr Endocrinol Metab 2000;13:709-715.
-
Roger M, Lahlou N, Chaussain JL: Gonadotropin-releasing hormone testing in pediatrics; in Ranke MB (ed): Diagnostics of Endocrine Function in Children and Adolescents. Heidelberg, Johann Ambrosius Barth Verlag, 1996, pp 346-369.
- Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF: Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-1429.
- Houk CP, Kunselman AR, Lee PA: Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 2009;123:e1059-e1063.
- De Vries L, Horev G, Schwartz M, Phillip M: Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature telarche. Eur J Endocrinol 2006;154:891-898.
- De Vries L, Phillip M: Role of pelvic ultrasound in girls with precocious puberty. Horm Res Paediatr 2011;75:148-152.
- Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR: Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-e762.
- Salardi S, Cacciari E, Maineti B, Mazzanti L, Pirazzoli P: Outcome of premature thelarche: relation to puberty and final height. Arch Dis Child 1998;79:173-174.
- Groome NP, Illingworth PJ, O'Brien M, Cooke I, Ganesan TS, Baird DT, McNeilly AS: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-1405.
- Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Müller J, Skakkebaek NE: Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone luteinizing hormone and estradiol levels. J Clin Endocrinol Metab 2000;85:1634-1640.
-
Istituto Superiore di Sanità: The surveillance system OKkio alla SALUTE: results 2010. Rapporti ISTISAN 12/14 (in Italian). 2012. http://www.iss.it/binary/publ/cont/dodici14web.pdf (accessed May 18, 2013).
- Kaplowitz P: Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab 2004;89:3644-3650.
- Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL: Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47-52.
- Pasternak Y, Friger M, Loewenthal N, Haim A, Hershkovitz E: The utility of basal serum LH in prediction of central precocious puberty in girls. Eur J Endocrinol 2012;166:295-299.
- Lahlou N, Roger M: Inhibin B in pubertal development and pubertal disorders. Semin Reprod Med 2004;22:165-175.
- Raivio T, Dunkel L: Inhibins in childhood and puberty. Best Pract Res Clin Endocrinol Metab 2002;16:43-52.
- Sehested A, Andresson AM, Müller J, Skakkebaek NE: Serum inhibin A and inhibin B in central precocious puberty before and during treatment with GnRH agonists. Horm Res 2000;54:84-91.
- Mogensen SS, Aksglaede L, Mouritsen A, Sørensen K, Main KM, Gideon P, Juul A: Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab 2011;96:1393-1401.
- Léger J, Raynaud R, Czernichow P: Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000;137:819-825.
- Lappöhn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn HW: Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989;32:790-793.
Article / Publication Details
Received: March 10, 2013
Accepted: July 25, 2013
Published online: September 17, 2013
Issue release date: October 2013
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
